Información del artículo
El Texto completo está disponible en PDF
References
[1.]
L. Fardet, A. Dupuy, M. Gain, A. Kettaneh, P. Chérin, H. Bachelez, et al.
Factors associated with underlying malignancy in retrospective cohort of 121 patients with dermatomyositis.
Medicine, 88 (2009), pp. 91-97
[2.]
A. Sparsa, E. Liozon, F. Herrmann, K. Ly, V. Lebrun, P. Soria, et al.
Routine vs extensive malignancy search for adult dermatomyositis and polymyositis: a study of 40 patients.
Arch Dermatol, 138 (2002), pp. 885-890
[3.]
J.P. Callen.
When and how should the patient with dermatomyositis or amyopathic dermatomyositis be assessed for possible cancer?.
Arch Dermatol, 138 (2002), pp. 969-971
[4.]
E. Mahé, V. Descamps, M. Burnouf, B. Crickx.
A helpful clinical sign predictive of cancer in adult dermatomyositis: cutaneous necrosis.
Arch Dermatol, 139 (2003), pp. 539
[5.]
Y.J. Chen, C.Y. Wu, J.L. Shen.
Predicting factors of malignancy in dermatomyositis and polymyositis: a case-control study.
Br J Dermatol, 144 (2001), pp. 825-831
[6.]
I. Bielsa.
Nuevos anticuerpos en la dermatomiositis.
Actas Dermosifiliogr, 100 (2009), pp. 182-189
[7.]
H. Chinoy, N. Fertig, C.V. Oddis, W.E. Ollier, R.G. Cooper.
The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis.
Ann Rheum Dis, 66 (2007), pp. 1345-1349
Copyright © 2010. Academia Española de Dermatología y Venereología and Elsevier España, S.L.
